A sterile pharmaceutical composition is disclosed for repairing a vascular injury caused by vascular insufficiency. The composition comprises: (a) a vascular injury-repairing amount of a sterile chemotactic hematopoietic stem cell product, the vascular injury-repairing amount being effective to repair a vascular injury caused by vascular insufficiency, the chemotactic hematopoietic stem cell product comprising a nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells, which further contains a subpopulation of potent CD34+ cells that express CXCR-4 and that have CXCR-4-mediated chemotactic activity, and (b) a stabilizing amount of serum, wherein the stabilizing amount of serum is greater than 20% (v/v), wherein the pharmaceutical composition is further characterized as having the following properties for at least 24 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through a catheter: (i) at least 70% of CD34+ cells, (ii) contains a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity； (iii) is at least about 70% viable； and (iv) is able to form hematopoietic colonies in vitro.
